Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
Park
Tae Sung
TS
Cheong
June-Won
JW
Kim
Soo Jeong
SJ
Lee
Kyung Woo
KW
Song
Jaewoo
J
Lee
Kyung-A
KA
Suh
Borum
B
Song
Sungwook
S
Choi
Jong Rak
JR
D019943:Amino Acid Substitution / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D001549:Benzamides; D002888:Chromosomes, Human, Pair 19; D002893:Chromosomes, Human, Pair 3; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D018698:Glutamic Acid / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D020125:Mutation, Missense; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D014178:Translocation, Genetic; D014314:Trisomy; D014633:Valine / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D018698:Glutamic Acid; D000068877:Imatinib Mesylate; D014633:Valine